GlassScriptPhysician profile
Stephen M Heupler
NPI 1538261474
$1,551.21
in general payments reported to CMS, 2019-2025
22 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $158 · 2021: $88.53 · 2023: $266 · 2024: $404 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $235.53 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $223.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $123.47 | 2020-2025 | Farxiga, Airsupra |
| Amgen INC. | $118.58 | 2019-2024 | Repatha |
| Amarin Pharma, INC. | $118.47 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.69 | 2021-2025 | |
| Scpharmaceuticals INC. | $70.55 | 2025 | |
| Novo Nordisk INC | $68.64 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Siemens Medical Solutions USA, INC. | $65.68 | 2021 | |
| Merck Sharp & Dohme LLC | $59.17 | 2023 | Verquvo, Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.38 | 2020-2023 | Jardiance |
| Daiichi Sankyo INC. | $55.90 | 2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $54.99 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.66 | 2019 | |
| Edwards Lifesciences Corporation | $38.53 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $37.82 | 2019 | |
| Inspire Medical Systems, INC. | $21.74 | 2025 | Inspire |
| Genzyme Corporation | $20.05 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.39 | 2024 | Opsumit |
| Janssen Pharmaceuticals, INC | $12.41 | 2019 | |
| Pfizer INC. | $11.99 | 2019 | |
| Abbott Laboratories | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Heupler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.